Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Cureus ; 15(9): e45405, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37854752

ABSTRACT

Polycystic ovarian syndrome (PCOS), also referred to as Stein-Leventhal syndrome, happens to be one of most common hormonal disorders found in females, causing large-sized ovaries with small cysts of non-ovulated oocytes in the outer medulla part of the ovary. Women suffering from PCOS often exhibit symptoms like oligomenorrhoea, elevated testosterone levels, acne, alopecia, hirsutism, sudden weight gain and many more. It can predispose a woman to developing infertility in future, and thus, difficulties in conceiving; due to the cystic changes in the ovaries, it results in anovulation and amenorrhea. The early symptoms of PCOS are being commonly observed nowadays in young women who are in their early 20s and those who are overweight or obese. The metabolic expression of PCOS increases with obesity. Obesity is a factor that is considered to contribute the most in the occurrence of various long-standing and non-transmissible illnesses apart from PCOS such as atherosclerosis, hypertension, diabetes, high blood cholesterol and even certain types of cancers. In obesity, there is an increase in the size and number of fat cells in the body. Obese and overweight young girls have a heightened likelihood of developing PCOS and its corresponding metabolic and reproductive health complications.

2.
Int J Risk Saf Med ; 34(4): 337-355, 2023.
Article in English | MEDLINE | ID: mdl-37154184

ABSTRACT

BACKGROUND: Acinetobacter baumannii is a major cause of nosocomial infections and high mortality rates. Evaluation of risk factors for such resistant infections may aid surveillance and diagnostic initiatives, as well as, can be crucial in early and appropriate antibiotic therapy. OBJECTIVE: To identify the risk factors in patients with resistant A. baumannii infection with respect to controls. METHODS: Prospective or retrospective cohort and case-control studies reporting the risk factors for resistant A. baumannii infection were collected through two data sources, MEDLINE/PubMed and OVID/Embase. Studies published in the English language were included while animal studies were excluded. The Newcastle-Ottawa Scale was used to assess the quality of studies. The odds ratio of developing antibiotic resistance in patients with A. baumannii infection was pooled using a random-effect model. RESULTS: The results are based on 38 studies with 60878 participants (6394 cases and 54484 controls). A total of 28, 14, 25, and 11 risk factors were identified for multi-drug resistant (MDRAB), extensive-drug resistant (XDRAB), carbapenem-resistant (CRAB) and imipenem resistant A. baumannii infection (IRAB), respectively. In the MDRAB infection group, exposure to carbapenem (OR 5.51; 95% CI: 3.88-7.81) and tracheostomy (OR 5.01; 95% CI: 2.12-11.84) were identified with maximal pool odd's ratio. While previous use of amikacin (OR 4.94; 95% CI: 1.89-12.90) and exposure to carbapenem (OR 4.91; 95% CI: 2.65-9.10) were the foremost factors associated with developing CRAB infection. Further analysis revealed, mechanical ventilation (OR 7.21; 95% CI: 3.79-13.71) and ICU stay (OR 5.88; 95% CI: 3.27-10.57) as the most significant factors for XDRAB infection. CONCLUSION: The exposure of carbapenem, amikacin (previous) and mechanical ventilation were the most significant risk factors for multidrug, extensive-drug, and carbapenem resistance in patients with A. baumannii infection respectively. These findings may guide to control and prevent resistant infections by identifying the patients at higher risk of developing resistance.


Subject(s)
Acinetobacter Infections , Acinetobacter baumannii , Cross Infection , Humans , Retrospective Studies , Prospective Studies , Amikacin/therapeutic use , Amikacin/pharmacology , Drug Resistance, Multiple, Bacterial , Acinetobacter Infections/drug therapy , Acinetobacter Infections/epidemiology , Carbapenems/pharmacology , Carbapenems/therapeutic use , Cross Infection/drug therapy , Cross Infection/epidemiology , Risk Factors
3.
Cureus ; 14(11): e31005, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36475226

ABSTRACT

Bionanotechnology is a budding area that combines engineering and biomedical sciences through the development of new functional systems and devices, especially related to medical use and their applications. DNA nanotechnology is one of the most widely studied fields for highly selective biosensing, imaging, drug delivery, and diagnostic purposes. Nanotechnology efficiently serves as a bridge between biotechnology and medical technology, and it offers great potential for medical and healthcare improvements. This has aroused a lot of scientific importance in the last few years owing to their exceptional practical capabilities and growing implementations in industrial and healthcare mechanics. Now, various research is being conducted to understand how nanoparticles can alter DNA sequences and their structures. Recent experiments using circular dichroism and fluorescence tests show that nanoparticle binding produces a flexible conformational shift in the structure of DNA. Additionally, the nanoparticle's affinity for the DNA may very well be influenced by external agents, albeit the complex is stable at rather high ionic firmness. This review gives an account of the mechanism of DNA-nanoparticle binding, with the binding of distinct types of nanoparticles and their interactions, how they change the structure of DNA, and their therapeutic uses and talks about their cytotoxic effects on humans and the environment.

4.
Cureus ; 14(9): e29366, 2022 Sep.
Article in English | MEDLINE | ID: mdl-36304358

ABSTRACT

The late Nobel Physicist Richard P. Feynman, in a dinner talk in 1959, very rightly said that there is enough room for the betterment of technology beyond our scope of imagination, proposing utilizing mechanical tools to make those that are relatively smaller than the others, which further can be rendered fruitful in making even more compact mechanical devices, all the way down to the level of the smallest known atom, emphasizing that this is "a progress which I believe cannot be avoided". Feynman proposed that nanomachines, nanorobots, and nanodevices may eventually be utilized to construct a huge range of atomically accurate microscopic instruments and manufacturing equipment, as well as a large number of ultra-small devices and other nanoscale and microscale robotic structures. Biotechnology, molecular biology, and molecular medicine could be used to create totally self-sufficient nanorobots/nanobots. Nanorobotics includes sophisticated submicron devices constructed of nanocomponents that are viewed as a magnificent desired future of health care. It has a promising potential in medication delivery technology for cancer, the top cause of mortality among those under the age of 85 years. Nanorobots might transport and distribute vast volumes of anticancer medications into diseased cells without hurting normal cells, decreasing the adverse effects of existing therapies such as chemotherapy damage. The ultimate development of this innovation, which will be accomplished via a close partnership among specialists in robotics, medicine, and nanotechnology, will have a significant influence on illness detection, therapy, and prophylaxis. This report includes a study on several ways to cancer therapy utilizing nanorobots. Furthermore, it offers insight into the future breadth of this area of research.

SELECTION OF CITATIONS
SEARCH DETAIL
...